Clinical significance of gross morphological type beyond tumor burden in hepatocellular carcinoma treated with atezolizumab plus bevacizumab [0.03%]
阿特朱单抗联合贝伐珠单抗治疗肝细胞癌的宏观类型意义超出了肿瘤负荷的临床意义
Seonjeong Woo,Donghyeon Kim,Chansik An et al.
Seonjeong Woo et al.
2026 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma [0.03%]
2026年KLCA-NCC韩国肝细胞癌管理实践指南
Korean Liver Cancer Association (KLCA);National Cancer Center (NCC) Korea
Korean Liver Cancer Association (KLCA);National Cancer Center (NCC) Korea
Alcohol-aware risk stratification and subtype-specific care pathways across metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease [0.03%]
针对代谢功能障碍相关肝内脂质蓄积性肝病、代谢功能障碍和酒精相关性肝病以及酒精相关性肝病的风险分层和亚型特异性诊疗路径的酒精风险意识模型
Hyo Young Lee,Eileen Laurel Yoon,Dae Won Jun
Hyo Young Lee
Accurate classification and risk stratification across metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD) depend ...
Comprehensive Radiopathological and Molecular Review of HCC: Expanding on the WHO, 6th Edition [0.03%]
肝细胞癌的放射病理和分子综合审查——超越WHO第6版
Hyungjin Rhee,Young Nyun Park
Hyungjin Rhee
Hepatocellular carcinoma (HCC) exhibits substantial molecular and morphological heterogeneity. The recently updated 6th edition of the World Health Organization Classification of Digestive Tumours recognizes nine specific HCC subtypes, each...
Viral load rather than transaminase: an international perspective on the KASL-EALA 2026 guideline for chronic hepatitis B [0.03%]
病毒载量而非转氨酶：国际视角下的2026年KASL-EALA慢性乙型肝炎指南
Tatsuya Kanto,Fabien Zoulim,Ming-Lung Yu
Tatsuya Kanto
Erratum to 'MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on "Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study"' [Clin Mol Hepatol 2025;31:e128-e133] [0.03%]
关于“MAFLD或MASLD：哪一种更准确地代表了脂肪性肝脏人群的预后？——对“代谢功能障碍相关脂肪性肝病的进化变化及其与肝细胞癌风险的关系：一项全国队列研究”的编辑来信的勘误[clin mol hepatol 2025;31:e128-e133]
Ying Wang,Shengfeng Wang,Xiude Fan et al.
Ying Wang et al.
Published Erratum
Clinical and molecular hepatology. 2026 Jul;32(3):1472. DOI:10.3350/cmh.2024.1008e 2026
Correspondence to letter to the editor on "Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features" [0.03%]
关于“整合多组学谱型识别出浸润性肝细胞癌是一种具有独特分子特征的免疫治疗耐药亚型”的来信答复
Won Suk Lee,Seonjeong Woo,Sohyun Hwang et al.
Won Suk Lee et al.
From linear methylation to spatial metabolic control: Rethinking DNMT1 targeting in MASLD: Letter to the editor on "DNMT1 facilitates the progression of MASLD by impeding transcription mediated by HNF4α and PPARα" [0.03%]
从线性甲基化到空间代谢控制：对“DNMT1通过阻碍HNF4α和PPARα介导的转录促进MASLD进展”的重新思考：致编辑信函
Yao Liu,Qitai Song,Muhu Chen
Yao Liu